Quantbot Technologies LP Purchases Shares of 13,950 Enfusion, Inc. (NYSE:ENFN)

Quantbot Technologies LP acquired a new position in Enfusion, Inc. (NYSE:ENFN) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 13,950 shares of the company’s stock, valued at approximately $144,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Paloma Partners Management Co bought a new stake in Enfusion during the third quarter valued at about $157,000. Intech Investment Management LLC bought a new stake in Enfusion during the 4th quarter valued at approximately $191,000. Centiva Capital LP lifted its holdings in Enfusion by 5.0% in the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock worth $243,000 after purchasing an additional 1,227 shares in the last quarter. Azora Capital LP boosted its stake in Enfusion by 6.8% in the 3rd quarter. Azora Capital LP now owns 29,827 shares of the company’s stock worth $283,000 after purchasing an additional 1,890 shares during the period. Finally, Rhumbline Advisers grew its holdings in Enfusion by 3.0% during the 4th quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock valued at $643,000 after buying an additional 1,796 shares in the last quarter. 81.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Enfusion news, CFO Bradley Herring sold 4,134 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total transaction of $41,877.42. Following the completion of the sale, the chief financial officer now owns 266,369 shares in the company, valued at $2,698,317.97. This represents a 1.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Oleg Movchan sold 2,771 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total value of $28,070.23. Following the sale, the chief executive officer now directly owns 526,702 shares in the company, valued at $5,335,491.26. This trade represents a 0.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 77,346 shares of company stock valued at $868,109 over the last quarter. 36.44% of the stock is owned by corporate insiders.

Enfusion Stock Down 0.3 %

Shares of Enfusion stock opened at $11.11 on Monday. The stock’s fifty day moving average is $11.18 and its two-hundred day moving average is $10.21. Enfusion, Inc. has a 52 week low of $7.83 and a 52 week high of $11.80. The company has a market capitalization of $1.43 billion, a PE ratio of 277.69, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95.

Enfusion (NYSE:ENFN) last posted its quarterly earnings results on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). The company had revenue of $52.94 million during the quarter, compared to analysts’ expectations of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. As a group, research analysts anticipate that Enfusion, Inc. will post 0.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ENFN. Piper Sandler upped their target price on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. Stifel Nicolaus increased their price objective on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Finally, William Blair reiterated a “market perform” rating on shares of Enfusion in a report on Monday, January 13th.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.